CAMRESE LO Rx
Generic Name and Formulations:
Levonorgestrel 0.1mg, ethinyl estradiol 20mcg (84 tabs); ethinyl estradiol 10mcg (7 tabs).
Indications for CAMRESE LO:
1 tab daily for 91 days; repeat. Use Sunday-start regimen. Take pills in order (84 levonorgestrel + ethinyl estradiol tabs, then 7 ethinyl estradiol tabs).
Premenarchal: not recommended.
High risk of arterial or venous thrombotic disease (eg, smokers or migraineurs over age 35, history of DVT or thromboembolism, cerebrovascular or coronary artery disease, thrombogenic valvular disease, atrial fibrillation, subacute bacterial endocarditis, hypercoagulopathies, uncontrolled hypertension, diabetes with vascular disease, headaches with focal neurologic symptoms). Breast or other estrogen or progestin-sensitive neoplasms. Hepatic disease or tumors. Undiagnosed abnormal uterine bleeding. Pregnancy.
Discontinue if thrombotic event, unexplained visual changes, or jaundice occurs, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism. Gallbladder disease. Diabetes. Prediabetes. Uncontrolled dyslipidemias. Hypertriglyceridemia. Pregnancy-related cholestasis. Depression. Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea. Monitor blood pressure. Do regular complete physical exams. Nursing mothers: not recommended.
May be antagonized by CYP3A4 or other enzyme inducers (eg, barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John’s wort, topiramate); use backup contraception. May be affected by protease inhibitors, NNRTIs, atorvastatin, acetaminophen, ascorbic acid, itraconazole, ketoconazole. May antagonize lamotrigine. May affect laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). May need dose adjustment of thyroid hormones.
Progestin + estrogen.
Headache, nausea, vomiting, bleeding irregularities, dysmenorrhea, weight change, mastodynia, acne, abdominal pain, anxiety, depression; angioedema, chloasma, others (see full labeling).
Tablet dispenser—2 x 91 tablets
Endocrinology Advisor Articles
- ACP Defends Higher Blood Glucose Targets for Type 2 Diabetes
- Updated Clinical Practice Guidelines on Testosterone Therapy in Men With Hypogonadism
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Once-Daily Oral Contraceptive for Men Shows Promise
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures
- Common Plant-Derived Oils May Contain Endocrine-Disrupting Chemicals
- Red Meat Consumption Linked to Insulin Resistance and Steatohepatitis
- Effect of High Androgen Levels on Cardiovascular Risk in Postmenopausal Women
- Fertility in Women Negatively Affected by Asthma Medications
- Glucocorticoid Use in COPD Does Not Increase Fracture Risk